U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H31ClO7
Molecular Weight 466.952
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LOTEPREDNOL ETABONATE

SMILES

CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl

InChI

InChIKey=DMKSVUSAATWOCU-HROMYWEYSA-N
InChI=1S/C24H31ClO7/c1-4-30-21(29)32-24(20(28)31-13-25)10-8-17-16-6-5-14-11-15(26)7-9-22(14,2)19(16)18(27)12-23(17,24)3/h7,9,11,16-19,27H,4-6,8,10,12-13H2,1-3H3/t16-,17-,18-,19+,22-,23-,24-/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H31ClO7
Molecular Weight 466.952
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

1998
123
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28017774
LOTEPREDNOL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 drop 4 times / day multiple, topical
Recommended
Dose: 1 drop, 4 times / day
Route: topical
Route: multiple
Dose: 1 drop, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9124242
unhealthy, 3.4 ± 1.1
Health Status: unhealthy
Age Group: 3.4 ± 1.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9124242
Disc. AE: Intraocular pressure increased...
AEs leading to
discontinuation/dose reduction:
Intraocular pressure increased (2.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9124242
AEs

AEs

AESignificanceDosePopulation
Intraocular pressure increased 2.8%
Disc. AE
1 drop 4 times / day multiple, topical
Recommended
Dose: 1 drop, 4 times / day
Route: topical
Route: multiple
Dose: 1 drop, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9124242
unhealthy, 3.4 ± 1.1
Health Status: unhealthy
Age Group: 3.4 ± 1.1
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9124242
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:08:21 GMT 2025
Edited
by admin
on Mon Mar 31 18:08:21 GMT 2025
Record UNII
YEH1EZ96K6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LOTEPREDNOL ETABONATE
JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
INVELTYS
Preferred Name English
ZYLET COMPONENT LOTEPREDNOL ETABONATE
Common Name English
Chloromethyl 11?,17-dihydroxy-3-oxoandrosta-1,4-diene-17?-carboxylate, 17-(ethyl carbonate)
Common Name English
P-5604
Code English
LOTEPREDNOL ETABONATE [VANDF]
Common Name English
LOTEPREDNOL ETABONATE [USAN]
Common Name English
CDDD5604
Code English
HGP-1
Code English
Loteprednol etabonate [WHO-DD]
Common Name English
EYSUVIS
Brand Name English
ALREX
Brand Name English
LOTEPREDNOL ETABONATE [MART.]
Common Name English
ANDROSTA-1,4-DIENE-17-CARBOXYLIC ACID, 17-((ETHOXYCARBONYL)OXY)-11-HYDROXY-3-OXO-, CHLOROMETHYL ESTER, (11.BETA.,17.ALPHA.)-
Systematic Name English
LOTEPREDNOL ETABONATE [JAN]
Common Name English
CDDD-5604
Code English
LOTEMAX
Brand Name English
KPI-121
Code English
LOTEPREDNOL ETABONATE [MI]
Common Name English
LOTEPREDNOL ETABONATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID2046468
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
FDA UNII
YEH1EZ96K6
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
DAILYMED
YEH1EZ96K6
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
DRUG BANK
DB00873
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
RXCUI
52177
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m6912
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY Merck Index
SMS_ID
100000076769
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
IUPHAR
7085
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
USAN
BB-79
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
EVMPD
SUB14390MIG
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
ChEMBL
CHEMBL1200865
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
PUBCHEM
444025
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
CAS
82034-46-6
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
NCI_THESAURUS
C47589
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
DRUG CENTRAL
1611
Created by admin on Mon Mar 31 18:08:21 GMT 2025 , Edited by admin on Mon Mar 31 18:08:21 GMT 2025
PRIMARY
Related Record Type Details
GLUCOCORTICOID RECEPTOR
TARGET -> AGONIST
Related Record Type Details
Structure of LOTEPREDNOL ETABONATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966